Contact
searchSearch
HMP Global
Login

Comparative Effectiveness Research Resource Center

Featured

News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Cancer Care Equity and Collaboration
10/16/2022
At the 2022 Oncology Clinical Pathways Congress, Lawrence N Shulman, MD, Abramson Cancer Center University of Pennsylvania, summarized the status of cancer care in the United States and proposed how collaborative care can enhance quality of...
At the 2022 Oncology Clinical Pathways Congress, Lawrence N Shulman, MD, Abramson Cancer Center University of Pennsylvania, summarized the status of cancer care in the United States and proposed how collaborative care can enhance quality of...
At the 2022 Oncology Clinical...
10/16/2022
Journal of Clinical Pathways
News
Ensartinib vs Crizotinib for ALK-Positive NSCLC
09/16/2021
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior...
09/16/2021
Journal of Clinical Pathways
News
Carboplatin Monotherapy vs Carboplatin Plus Paclitaxel for Older Women With Ovarian Cancer
05/12/2021
05/12/2021
Journal of Clinical Pathways
Quiz
Quiz: Acalabrutinib for Patients With CLL
04/19/2021
04/19/2021
Journal of Clinical Pathways
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
Videos
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
03/23/2021
03/23/2021
Journal of Clinical Pathways
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
Videos
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
03/18/2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses...
03/18/2021
Journal of Clinical Pathways
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
Videos
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
02/24/2021
02/24/2021
Journal of Clinical Pathways
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Videos
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
02/23/2021
02/23/2021
Journal of Clinical Pathways
News
Sequential or Concurrent Chemoradiation vs Radiation Alone After Hysterectomy for Cervical Cancer
01/28/2021
01/28/2021
Journal of Clinical Pathways

News

News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
News
Ensartinib vs Crizotinib for ALK-Positive NSCLC
09/16/2021
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior...
09/16/2021
Journal of Clinical Pathways
News
Carboplatin Monotherapy vs Carboplatin Plus Paclitaxel for Older Women With Ovarian Cancer
05/12/2021
05/12/2021
Journal of Clinical Pathways
News
Sequential or Concurrent Chemoradiation vs Radiation Alone After Hysterectomy for Cervical Cancer
01/28/2021
01/28/2021
Journal of Clinical Pathways
News
Comparative Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
01/27/2021
01/27/2021
Journal of Clinical Pathways
News
Targeted Gene Testing-Directed Treatment Cost-Effective for Metastatic GIST
10/06/2020
10/06/2020
Journal of Clinical Pathways
News
No Significant PFS Improvement With KRd Vs VRd in Newly Diagnosed MM
10/01/2020
10/01/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Larotrectinib Vs Entrectinib for Metastatic NSCLC
09/09/2020
09/09/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice
09/03/2020
09/03/2020
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
News
Addressing Racial and Ethnic Disparities in Cancer Clinical Trial Access
12/06/2024
Despite research advancements, racial and ethnic inequities continue to occur in cancer clinical trial participation, exacerbating disparities in access to investigational therapies. A recent study published in JNCI Cancer Spectrum explored...
Despite research advancements, racial and ethnic inequities continue to occur in cancer clinical trial participation, exacerbating disparities in access to investigational therapies. A recent study published in JNCI Cancer Spectrum explored...
Despite research advancements,...
12/06/2024
Journal of Clinical Pathways
News
Enhanced AI Model Outperforms Traditional Techniques in Endometrial Cancer Diagnosis
12/06/2024
A cutting-edge artificial intelligence (AI) model significantly improves the accuracy and efficiency of diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence compared to traditional methods.
A cutting-edge artificial intelligence (AI) model significantly improves the accuracy and efficiency of diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence compared to traditional methods.
A cutting-edge artificial...
12/06/2024
Journal of Clinical Pathways
News
Bridging the Gap: Addressing Disparities in Cervical, Endometrial, and Ovarian Cancer Trials and Care in the US
11/27/2024
According to a recent study published in JAMA Network Open, gynecological cancers in the US disproportionately impact marginalized racial and ethnic groups. Mortality rates for cervical, endometrial, and ovarian cancers are notably higher...
According to a recent study published in JAMA Network Open, gynecological cancers in the US disproportionately impact marginalized racial and ethnic groups. Mortality rates for cervical, endometrial, and ovarian cancers are notably higher...
According to a recent study...
11/27/2024
Journal of Clinical Pathways
News
Evaluating Lenvatinib and Pembrolizumab as a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer
11/27/2024
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the...
11/27/2024
Journal of Clinical Pathways
News
Antilymphocyte Globulin Improves Outcomes in Patients With Myelofibrosis Undergoing Stem Cell Transplantation
11/22/2024
Using antithymocyte/antilymphocyte globulin (ATLG) in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) may improve graft-versus-host disease-free and relapse-free survival (GRFS) rates.
Using antithymocyte/antilymphocyte globulin (ATLG) in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) may improve graft-versus-host disease-free and relapse-free survival (GRFS) rates.
Using...
11/22/2024
Journal of Clinical Pathways
News
Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer
11/19/2024
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
News
Thrombosis and Inflammation Drive Mortality and Cancer Risk in Myeloproliferative Disorders
11/15/2024
Despite the advancements in treatment, thrombosis remains a significant challenge for patients with myeloproliferative neoplasms (MPNs), leading to increased mortality and the development of secondary cancers.
Despite the advancements in treatment, thrombosis remains a significant challenge for patients with myeloproliferative neoplasms (MPNs), leading to increased mortality and the development of secondary cancers.
Despite the advancements in...
11/15/2024
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways

Videos

Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
Videos
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
03/23/2021
03/23/2021
Journal of Clinical Pathways
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
Videos
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
03/18/2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses...
03/18/2021
Journal of Clinical Pathways
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
Videos
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
02/24/2021
02/24/2021
Journal of Clinical Pathways
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Videos
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
02/23/2021
02/23/2021
Journal of Clinical Pathways
BDHC thumbnail
Videos
Precision Medicine in Oncology: From Testing to Therapy
12/05/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, explore the distinction between precision and personalized medicine, the challenges and nuances of next-generation sequencing (NGS) testing in...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, explore the distinction between precision and personalized medicine, the challenges and nuances of next-generation sequencing (NGS) testing in...
In this Breaking Down Health...
12/05/2024
Cancer Care Business Exchange
Matthew Davids, MD
Videos
Factors Impacting the Development and Selection of Targeted Therapies for Patients With CLL
12/04/2024
Matthew S. Davids, MD, speaks about the latest targeted therapies for treating CLL, the challenges in developing these treatments, and how they are being used in the community oncology setting.
Matthew S. Davids, MD, speaks about the latest targeted therapies for treating CLL, the challenges in developing these treatments, and how they are being used in the community oncology setting.
Matthew S. Davids, MD, speaks...
12/04/2024
Journal of Clinical Pathways
Videos
Driving Innovation in Cancer Care: The Future of Value-Based Care in Oncology
12/04/2024
In this interview, Gordon Kuntz discusses the Delphi Method, a Predictable Cost of Care Model developed by the Predictable Cost of Care Working Group that enhances oncology market access strategies by standardizing and broadening the economic...
In this interview, Gordon Kuntz discusses the Delphi Method, a Predictable Cost of Care Model developed by the Predictable Cost of Care Working Group that enhances oncology market access strategies by standardizing and broadening the economic...
In this interview, Gordon Kuntz...
12/04/2024
Journal of Clinical Pathways
Videos
Building Consensus for Predictable Cancer Care Costs: Applying the Delphi Method to Multidisciplinary Stakeholder Collaboration
12/02/2024
In this interview, Carole Tremonti, RN, MBA, discusses the critical role of clinical pathways in equitable cancer care, the application of the Delphi Method by the Predictable Cost of Care Working Group to foster multidisciplinary...
In this interview, Carole Tremonti, RN, MBA, discusses the critical role of clinical pathways in equitable cancer care, the application of the Delphi Method by the Predictable Cost of Care Working Group to foster multidisciplinary...
In this interview, Carole...
12/02/2024
Journal of Clinical Pathways
Danielle Brander, MD
Videos
Chronic Lymphocytic Leukemia Treatment Trends in Community Oncology Settings
11/26/2024
Danielle Brander, MD, highlights current trends in the community oncology setting for treating chronic lymphocytic leukemia (CLL) and how clinical pathways can assist oncologists with decision making for frontline therapy in CLL.
Danielle Brander, MD, highlights current trends in the community oncology setting for treating chronic lymphocytic leukemia (CLL) and how clinical pathways can assist oncologists with decision making for frontline therapy in CLL.
Danielle Brander, MD, highlights...
11/26/2024
Journal of Clinical Pathways
Videos
The Evolving Role of Pharmacists in Custom Pathway Implementation
11/25/2024
In this interview, Rebecca Maniago, PharmD, discusses the complexities of implementing custom clinical pathways, emphasizing the need for clear goals, robust resources, and ongoing updates, while highlighting the pivotal role of pharmacists...
In this interview, Rebecca Maniago, PharmD, discusses the complexities of implementing custom clinical pathways, emphasizing the need for clear goals, robust resources, and ongoing updates, while highlighting the pivotal role of pharmacists...
In this interview, Rebecca...
11/25/2024
Journal of Clinical Pathways
Danielle Brander, MD
Videos
Insights on BTK Inhibitors as Frontline Treatment for Chronic Lymphocytic Leukemia
11/22/2024
Danielle Brander, MD, discusses the latest National Comprehensive Cancer Network guidelines for chronic lymphocytic leukemia (CLL) and the efficacy of BTK inhibitors as monotherapy in the frontline treatment of CLL.
Danielle Brander, MD, discusses the latest National Comprehensive Cancer Network guidelines for chronic lymphocytic leukemia (CLL) and the efficacy of BTK inhibitors as monotherapy in the frontline treatment of CLL.
Danielle Brander, MD, discusses...
11/22/2024
Journal of Clinical Pathways
Chang Headshot
Videos
Optimizing Pathways in NSCLC With Immunotherapy and Radiation
11/22/2024
Joe Y. Chang, MD, PhD, explores advancements in NSCLC treatment pathways, emphasizing the integration of immunotherapy and precision radiotherapy, the role of value-based care in palliative approaches, and the potential of artificial...
Joe Y. Chang, MD, PhD, explores advancements in NSCLC treatment pathways, emphasizing the integration of immunotherapy and precision radiotherapy, the role of value-based care in palliative approaches, and the potential of artificial...
Joe Y. Chang, MD, PhD, explores...
11/22/2024
Journal of Clinical Pathways
Kolodziej Headshot
Videos
Understanding the Impact of Venture Capital and Private Equity in Oncology
11/18/2024
Michael Kolodziej, MD, discusses the growing influence of venture capital and private equity in oncology care, highlighting the potential for these trends to reshape costs, partnerships, and innovation in the oncology landscape.
Michael Kolodziej, MD, discusses the growing influence of venture capital and private equity in oncology care, highlighting the potential for these trends to reshape costs, partnerships, and innovation in the oncology landscape.
Michael Kolodziej, MD, discusses...
11/18/2024
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Nov-Dec 2024 Issue Cover

Current Issue

December 2024
Volume 10
Issue 6
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Cancer Care Equity and Collaboration
10/16/2022
At the 2022 Oncology Clinical Pathways Congress, Lawrence N Shulman, MD, Abramson Cancer Center University of Pennsylvania, summarized the status of cancer care in the United States and proposed how collaborative care can enhance quality of...
At the 2022 Oncology Clinical Pathways Congress, Lawrence N Shulman, MD, Abramson Cancer Center University of Pennsylvania, summarized the status of cancer care in the United States and proposed how collaborative care can enhance quality of...
At the 2022 Oncology Clinical...
10/16/2022
Journal of Clinical Pathways
News
Ensartinib vs Crizotinib for ALK-Positive NSCLC
09/16/2021
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior...
09/16/2021
Journal of Clinical Pathways
News
Carboplatin Monotherapy vs Carboplatin Plus Paclitaxel for Older Women With Ovarian Cancer
05/12/2021
05/12/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use